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To the Editor—In a recent article [1], the authors
acknowledge that simulation (so-called “patient-level”
simulations) can appropriately handle the realities
required to correctly model most human disease pro-
cesses but fret that “computational expense” will limit
the provision of probabilistic sensitivity analyses (PSA)
currently in vogue. While we recognize that full char-
acterization of uncertainty is necessary to suitably
inform decisions about the adoption of new health
technologies, we do not share the authors’ concern. It is
the case that a model that is built at the required depth
[2] to reasonably inform decision-makers and deal with
uncertainty (including structural), variability, and het-
erogeneity will involve a large number of computations
and these can become a hindrance to conducting PSA.
The solution does not lie, however, with accepting
unnecessary compromises as the authors’ suggest.
Although cohort Markov models may involve fewer
calculations, they require gross oversimpliﬁcations
making them rarely suitable for informing real deci-
sions. Embarking on patches and partial, theoretically
weak, “semi-Markov” constructs and emulators adds
complexity without solving the problem. Instead, we
need to build computationally efﬁcient simulations and
use well-established techniques [3–5] to reduce nui-
sance variance and thus the number of replications
required.
The practical problems of increased computation
pale besides those caused by the signiﬁcant untenable
assumptions often required in a cohort model. For
example, age is usually an important determinant of
the course of illness and, in Markov processes, the
“mean” age assigned to the subcohort in each state is
increased typically by one time unit each cycle, ﬂa-
grantly ignoring that since age affects the transition
probabilities, the “mean” age will not increase in
such a linear fashion. There are many more reasons
than those noted by the authors for preferring indi-
vidual simulation: it allows for proper correlation
among characteristics—the well-known “clustering”
of risk factors, for example [6,7]; it permits correct
implementation of competing risks without recourse
to such peculiar solutions as applying risk equations
in random order [8]; it does not force the occurrence
of only a single transition within an often lengthy
cycle—people can develop an illness, be hospitalized,
suffer a complication and die, all within a day, if
appropriate; varying event sequences can be appro-
priately represented and medical decisions which are
not probabilistic can be fully incorporated; physi-
ologic parameters can change over time in clinically
relevant individual manner; limitations in resources
can be reﬂected directly as well as uncertainty in
their use and costs, to name just a few; and all of this
can be done without a massive proliferation of
“states,” tunnel constructs, and outside-of-model
programming.
Indeed, after building more than 100 Markov
models, many with semi-Markov constructs, and
now more than 30 simulations, we ﬁnd the latter tool
to be much easier to use, and the models are faster to
construct and much more transparent when com-
pleted. This comes at very little, if any, increase in
computation time. For example, our semi-Markov
diabetes model took 2.6 min (in Fortran) to compute
a cohort over a lifetime while our much more
complex diabetes simulation takes 2.1 min to do the
same for 1000 individual patients. Therefore, PSA
can be done as easily in the complex simulation. One
can create a model of type 2 diabetes that is “instan-
taneous,” but the result will reﬂect the disease and its
management so poorly that it will not be useful to
decision-makers.
If we as a profession aspire to inform real
decision-makers and actually inﬂuence decisions, then
we must see to it that our models are as realistic as
required and that the information we provide is as
detailed and rich as the questions that are posed to
us. Persuading decision-makers and analysts to opt
for inferior techniques does both them and our
ﬁeld a disservice. It is time for us to join the rest of
the scientiﬁc world and embrace simulation as the
standard modeling tool.—J. Jaime Caro, MDCM,
FRCPC, FACP, Caro Research Institute, and Division
of General Internal Medicine and Department of
Epidemiology, Biostatistics and Occupational Medi-
cine, McGill University, Montreal, PQ, Canada;
Denis Getsios, BSc, Montreal, PQ, Canada; Jörgen
Möller, BEng, Eslov, Sweden.
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